Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.40 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1275994 | 0.92 | NPC1 (0.48) | SMN1; SMN2NPC1RAB9AMAPTLMNA | |
| SCHEMBL12806037 | 0.88 | NPC1 (0.42) | SMN1; SMN2NPC1RAB9AMAPTGAA | |
| SCHEMBL12806256 | 0.86 | MEN1 (0.49) | MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL1275384 | 0.86 | RAB9A (0.47) | SMN1; SMN2NPC1RAB9APOLBGAA | |
| SCHEMBL18061042 | 0.86 | MAPT (0.41) | SMN1; SMN2NPC1RAB9AMAPTLMNA | |
| SCHEMBL12806084 | 0.86 | UCHL3 (0.51) | EGFRNUAK1NUAK2DRD3 | |
| SCHEMBL18060636 | 0.85 | JAK3 (0.45) | SMN1; SMN2MAPTPOLBEGFRNUAK1 | |
| SCHEMBL18060638 | 0.85 | JAK3 (0.45) | SMN1; SMN2MAPTPOLBEGFRNUAK1 | |
| SCHEMBL1275156 | 0.84 | TSHR (0.48) | MAPTPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL12806175 | 0.83 | AURKA (0.48) | MAPTLMNAKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758538-B2 | Heat shock protein binding compounds, compositions, and methods for making and using same | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3205647-B1 | 2-(PYRIMIDIN-5-YL)-THIOPYRIMIDINE DERIVATIVES AS HSP70 AND HSC70 MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-05-13 | — | — | EP | disclosed |
| US-20190038626-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2019-02-07 | — | — | US | disclosed |
| US-10052325-B2 | Heat shock protein binding compounds, compositions, and methods for making and using same | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2018-08-21 | — | — | US | disclosed |
| EP-3205647-A2 | 2-(PYRIMIDIN-5-YL)-THIOPYRIMIDINE DERIVATIVES AS HSP70 AND HSC70 MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Memorial Sloan-Kettering Cancer Center (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20170165265-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2017-06-15 | — | — | US | disclosed |
| US-9567318-B2 | Substituted pyrimidine compounds and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2017-02-14 | — | — | US | disclosed |
| WO-2011022440-A9 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2016-11-10 | — | — | WO | disclosed |
| EP-2467142-B1 | 2-(Pyrimidin-5-yl)-thiopyrimidine derivatives as Hsp70 and Hsc70 modulators for the treatment of proliferative disorders | SLOAN KETTERING INST CANCER (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20120252818-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2012-10-04 | — | — | US | disclosed |
| EP-2467142-A2 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | Memorial Sloan-Kettering Cancer Center (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011022440-A2 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165265-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | HSPBP1, HSF1, HSPA2 | SMN1; SMN2 270/4885NPC1 2801/4885RAB9A 4162/4885 |
| US-10758538-B2 | Heat shock protein binding compounds, compositions, and methods for making and using same | HSPBP1, HSF1, HSPA2 | SMN1; SMN2 270/4885NPC1 2801/4885RAB9A 4162/4885 |
| US-20120252818-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | HSPBP1, HSF1, HSPA2 | SMN1; SMN2 270/4885NPC1 2801/4885RAB9A 4162/4885 |
| US-20190038626-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | HSPBP1, HSF1, HSPA2 | SMN1; SMN2 270/4885NPC1 2801/4885RAB9A 4162/4885 |
| US-10052325-B2 | Heat shock protein binding compounds, compositions, and methods for making and using same | HSPBP1, HSF1, HSPA2 | SMN1; SMN2 270/4885NPC1 2801/4885RAB9A 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.